Lantheus Holdings (LNTH) Stock Forecast & Price Target

Lantheus Holdings is viewed favorably because 2026 has delivered multiple de-risking catalysts, including FDA approval of PYLARIFY TruVu in March, tentative approval for PNT2003, and an upcoming PDUFA decision for MK6240, while the FDA raised no safety or efficacy concerns for LNTH-2501. Financially, 1Q26 revenue rose to $377M versus $354M consensus and adjusted EPS was $1.46 versus $1.23, supported by a 67.0% gross margin and 34.2% adjusted operating margin. The outlook is further strengthened by Pylarify’s third consecutive quarter of flat-to-improving revenue at $241M, stable pricing and volumes, and the expected 4Q26 TruVu transition that should improve reimbursement, margins, and growth into 2027.

Lantheus Holdings is negative viewed because its business is overly concentrated, with PYLARIFY and DEFINITY representing over 80% of total sales in 2022, leaving results highly exposed to any slowdown, pricing pressure, or operational disruption in either platform. The company also faces meaningful execution risk from its radiopharmaceutical supply chain, which depends on reliable just-in-time manufacturing, a nationwide PMF and cyclotron network, and products with limited half-lives that make disruptions especially damaging. In addition, reimbursement and regulatory pressures remain a major headwind, since third-party payors and Medicare heavily influence patient access and could reduce demand if coverage or payments are tightened.